ArticleAntibody therapeutics2021
Challenges and Opportunities to Develop Enediyne Natural Products as Payloads for Antibody-Drug Conjugates.
Article in Antibody therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Homo-Clavulyne: Evaluation of a One-Atom Ring Expansion Strategy to Stabilize the Nine-Membered Ring Enediyne Biosynthetic Precursor.Synthesis · 2026Article
- DVD-IgG1 antibody-drug conjugates: Expanding the landscape of targeted cancer therapy.Current opinion in chemical biology · 2026Review
- Microbial-Derived Anti-Cancer Compounds: Advances in Drug Discovery, Bioengineering, and Therapeutic Applications.Anti-cancer agents in medicinal chemistry · 2026Review
- Chemotherapeutic Drug-Antibody Conjugates (ChemoBodies): Recent Advances and Future Directions.Current oncology reports · 2025Review
- Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy.Discover oncology · 2025Review
- Therapeutic antibodies in oncology: an immunopharmacological overview.Cancer immunology, immunotherapy : CII · 2024Review
- Enediyne natural product biosynthesis unified by a diiodotetrayne intermediate.Nature chemical biology · 2024Article
- Antibody Drug Conjugates for Cancer Therapy: From Metallodrugs to Nature-Inspired Payloads.International journal of molecular sciences · 2024Review
- Genome mining for new enediyne antibiotics.Current opinion in chemical biology · 2024Review
- Combinatorial metabolic engineering of Streptomyces sp. CB03234-S for the enhanced production of anthraquinone-fused enediyne tiancimycins.Microbial cell factories · 2024Article
- Anti-HER2 Immunoliposomes: Antitumor Efficacy Attributable to Targeted Delivery of Anthraquinone-Fused Enediyne.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- The Tangential Dialogue Between Science and Medicine: A Case in Point.Pediatric neurology · 2024Review
- Cofactorless oxygenases guide anthraquinone-fused enediyne biosynthesis.Nature chemical biology · 2024Article
- Dynemicin A Derivatives as Potential Cancer Chemotherapeutics by Mutasynthesis.Helvetica chimica acta · 2023Article
- Antibody-drug conjugates: Recent advances in payloads.Acta pharmaceutica Sinica. B · 2023Review
- A discrete intermediate for the biosynthesis of both the enediyne core and the anthraquinone moiety of enediyne natural products.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Application of a Biocatalytic Strategy for the Preparation of Tiancimycin-Based Antibody-Drug Conjugates Revealing Key Insights into Structure-Activity Relationships.Journal of medicinal chemistry · 2023Article
- Intramolecular C-C Bond Formation Links Anthraquinone and Enediyne Scaffolds in Tiancimycin Biosynthesis.Journal of the American Chemical Society · 2022Article
- Functionalized 10-Membered Aza- and Oxaenediynes through the Nicholas Reaction.Molecules (Basel, Switzerland) · 2022Article
- Deciphering the pathway-specific regulatory network for production of ten-membered enediyne Tiancimycins in Streptomyces sp. CB03234-S.Microbial cell factories · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Calicheamicin, the payload of the antibody-drug-conjugates (ADCs) gemtuzumab ozogamicin (Mylotarg
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.